DoW Peer Reviewed Medical, Lifestyle and Applied Health Research Award
- Response deadline
- Aug 6, 2026 Closed
- Date posted
- May 8, 2026
- Source
- Open notice
Description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Lifestyle and Applied Health Research Award supports clinical research and/or clinical trials using a combination of scientific disciplines including occupational science, psychology, psychometrics, biostatistics and epidemiology, surveillance, implementation science, and population health. Applications must address and provide a solution to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. Distinctive Features: This funding opportunity requires patient advocate participation. The patient advocate will be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas. Animal research is not allowed. Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $16.8M to fund approximately four Lifestyle and Applied Health Research Award applications with total cost caps of $4.2M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Classifications
- NAICS12.420
Documents (1)
- DownloadHT942526PRMRPLAHRA_GG.pdfapplication/pdf1.1 MB
Contacts
- help@ebrap.org301-619-1139
Similar contracts
- DoW Breast Cancer, Breakthrough Award Levels 1 and 2Due Nov 18, 2026
- DoW Breast Cancer, Clinical Research Extension AwardDue Nov 18, 2026
- DoW Reconstructive Transplant, Investigator-Initiated Research AwardDue Nov 4, 2026
- DoW Neurofibromatosis Research Academy – Scholar AwardDue Sep 22, 2026
- DoW Neurofibromatosis Investigator-Initiated Research AwardDue Sep 22, 2026
- DoW Neurofibromatosis Exploration-Hypothesis Development AwardDue Sep 22, 2026